Scarica l'app Stockscreener
18.39
2.48%
0.445
Panoramica
Notizia
Cronologia dei prezzi
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$17.95
Aprire:
$18.07
Volume 24 ore:
249.63K
Relative Volume:
0.93
Capitalizzazione di mercato:
$501.86M
Reddito:
$11.88M
Utile/perdita netta:
$-162.08M
Rapporto P/E:
-1.4735
EPS:
-12.484
Flusso di cassa netto:
$-156.43M
1 W Prestazione:
+4.70%
1M Prestazione:
-7.89%
6M Prestazione:
+47.28%
1 anno Prestazione:
+38.62%
Intervallo 1D:
$17.75
$18.77
Intervallo di 1 settimana:
$17.05
$19.05
Portata 52W:
$8.72
$27.41
Crescent Biopharma Inc Stock (CBIO) Company Profile
Nome
Crescent Biopharma Inc
Settore
Industria
Telefono
617-430-5595
Indirizzo
300 FIFTH AVENUE, WALTHAM, CA
Compare CBIO vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CBIO
Crescent Biopharma Inc
|
18.20 | 501.59M | 11.88M | -162.08M | -156.43M | -12.48 |
VRTX
Vertex Pharmaceuticals Inc
|
459.29 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
610.86 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
894.11 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
279.92 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
159.85 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Crescent Biopharma Inc Stock (CBIO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-28 | Iniziato | Piper Sandler | Overweight |
| 2026-01-21 | Iniziato | Guggenheim | Buy |
| 2025-08-25 | Iniziato | Jefferies | Buy |
| 2025-08-11 | Iniziato | H.C. Wainwright | Buy |
| 2025-07-14 | Iniziato | Wedbush | Outperform |
| 2025-06-25 | Iniziato | Stifel | Buy |
| 2025-03-21 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-03-11 | Iniziato | Noble Capital Markets | Outperform |
| 2024-07-26 | Downgrade | TD Cowen | Buy → Hold |
| 2023-12-22 | Iniziato | CapitalOne | Overweight |
| 2021-11-12 | Aggiornamento | Jefferies | Hold → Buy |
| 2021-04-29 | Ripresa | Stephens | Overweight |
| 2021-02-10 | Iniziato | Piper Sandler | Overweight |
| 2020-05-21 | Iniziato | Raymond James | Outperform |
| 2019-11-14 | Iniziato | ROTH Capital | Buy |
| 2019-08-05 | Downgrade | Jefferies | Buy → Hold |
| 2019-08-05 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2019-08-05 | Downgrade | SunTrust | Buy → Hold |
| 2019-04-12 | Iniziato | Piper Jaffray | Overweight |
| 2019-01-04 | Iniziato | Oppenheimer | Outperform |
| 2018-12-18 | Iniziato | H.C. Wainwright | Buy |
| 2018-02-12 | Reiterato | B. Riley FBR, Inc. | Buy |
| 2018-02-09 | Reiterato | Chardan Capital Markets | Buy |
| 2017-12-08 | Iniziato | B. Riley FBR, Inc. | Buy |
| 2017-06-12 | Iniziato | Chardan Capital Markets | Buy |
| 2017-06-06 | Iniziato | Ladenburg Thalmann | Buy |
| 2016-07-26 | Iniziato | SunTrust | Buy |
| 2016-06-30 | Iniziato | Rodman & Renshaw | Buy |
| 2015-03-17 | Reiterato | Stifel | Buy |
Mostra tutto
Crescent Biopharma Inc Borsa (CBIO) Ultime notizie
Crescent Biopharma Announces Grants of Inducement Awards | Associated Press | syndication news - Enidnews.com
Crescent Biopharma Announces Grants of Inducement Awards - The Manila Times
CBIO: CR-001 and ADC pipeline aim for best-in-class oncology therapies, with pivotal data expected from 2027 - TradingView
HC Wainwright & Co. Initiates Coverage of Crescent Biopharma (CBIO) with Buy Recommendation - MSN
[Form 4] CRESCENT BIOPHARMA, INC. Insider Trading Activity - Stock Titan
Crescent Biopharma (CBIO) director receives grant of 11,050 stock options at $17.01 - Stock Titan
Crescent Biopharma director granted 11,050 options | CBIO Insider Trading - Stock Titan
Director at Crescent Biopharma (CBIO) receives option grant for 11,050 shares - Stock Titan
Fairmount-linked director awarded 11,050 CBIO options at $17.01 exercise price - Stock Titan
Crescent Biopharma shareholders back directors, pay and auditor - TipRanks
Crescent Biopharma (CBIO) investors back directors, auditor and annual say-on-pay - Stock Titan
Crescent Biopharma, Inc. to Present at Jefferies and Goldman Sachs Healthcare Conferences in June 2026 - Quiver Quantitative
Crescent Biopharma to Present at June Investor Conferences - GlobeNewswire
CBIO: Directors elected, auditor ratified, and executive compensation approved with annual advisory votes - TradingView
CBIO: All proposals, including director elections and auditor ratification, were approved - TradingView
Analysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD), Crescent Biopharma (CBIO) and Erasca (ERAS) - The Globe and Mail
Crescent Biopharma Rings the Nasdaq Stock Market Closing Bell - Nasdaq
Crescent Biopharma Rings the Closing Bell - Nasdaq
Crescent Biopharma downgraded by H.C. Wainwright - Quantisnow
H.C. Wainwright downgrades Crescent Biopharma stock rating to neutral By Investing.com - Investing.com South Africa
H.C. Wainwright downgrades Crescent Biopharma stock rating to neutral - Investing.com
CBIO Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Operational DisciplineEarnings Decline Risk - newsline.com
Crescent Biopharma (CBIO) Edges Lower, Holds Near Key Support LevelBlock Trade Flow - The Legal Advocate
CBIO Q1 2026 Earnings: EPS Beat on Lower Net Loss as Pipeline AdvancesEarnings Forecast Report - newsline.com
Crescent Biopharma (CBIO) Surges 4.59% as Biotech Sector Gains MomentumWMA Signal - The Legal Advocate
Crescent Biopharma (CBIO) Q1 2026 Earnings: Narrower Loss Beats Estimates; Shares Edge LowerFree Cash Flow Trends - The Legal Advocate
CBIO Q1 2026 Earnings: Narrowed Loss Beat Estimates as Clinical Pipeline AdvancesDownward Estimate Revision - newsline.com
Analysts Offer Insights on Healthcare Companies: Roivant Sciences (ROIV), Crescent Biopharma (CBIO) and Genmab (GMAB) - The Globe and Mail
CBIO: Four clinical studies launching in 2024 set up a data-rich 2027 for oncology pipeline decisions - TradingView
CBIO Q1 2026 Earnings: Narrower Loss Surprises, Pipeline Progress ContinuesDividend Growth Analysis - Newser
Crescent Biopharma Inc. (CBIO) Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost DisciplineDividend Cut Risk - Newser
Crescent Biopharma Announces Trial in Progress Presentation for ASCEND Study of CR-001, a PD-1 x VEGF Bispecific Antibody, at Upcoming American Society of Clinical Oncology (ASCO) 2026 Annual Meeting - Sahm
CBIO Q1 2026 Earnings: Narrowed Loss Beats Estimates as Clinical Pipeline ProgressesSegment Revenue Breakdown - The Legal Advocate
Crescent Biopharma (CBIO) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat
Crescent Biopharma to present CR-001 trial data at ASCO meeting - Investing.com Nigeria
Crescent Biopharma to present CR-001 trial data at ASCO meeting By Investing.com - Investing.com South Africa
Crescent Biopharma Announces Ongoing ASCEND Phase 1/2 Clinical Trial of CR-001 for Multiple Solid Tumor Types with Initial Data Expected in 2027 - Quiver Quantitative
Crescent Biopharma Announces Trial in Progress Presentation for ASCEND Study of CR-001, a PD-1 ... - Caledonian Record
Crescent cancer trial takes CR-001 to ASCO 2026, first data expected in 2027 - Stock Titan
Tang Capital entities disclose 1,160,000-share stake in Crescent Biopharma (CBIO) - Stock Titan
New Forecasts: Here's What Analysts Think The Future Holds For Crescent Biopharma, Inc. (NASDAQ:CBIO) - 富途牛牛
Balyasny entities disclose 1.51M shares in Crescent Biopharma (CBIO) - Stock Titan
Crescent Biopharma gives 5 new hires options on 129,075 shares - Stock Titan
Number of shareholders of Crescent Biopharma, Inc. – NASDAQ:CBIO - TradingView
CBIO Crescent Bio jumps 4% as Q1 loss beats estimates by 27%, pipeline progress lifts investor confidence.Trading Community - Newser
Crescent Biopharma Inc Azioni (CBIO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.79%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):